Almost all active pharmaceutical ingredients (APIs) are crystallized at some stage, and many are formulated as crystalline materials. A crystalline API must exhibit consistent physical properties from gram-scale development through multi-kilogram supply. Crystallization method development turns form selection into a reproducible manufacturing process.
The content of this page has been scientifically reviewed by Aeri Park, Ph.D., COO at Triclinic Labs · Updated 8/1/2026
The selected solid form is chosen for properties such as dissolution rate, bioavailability, stability, handling, or intellectual property. The crystallization process must selectively produce that form with high efficiency, chemical purity, and polymorphic purity.
Instead of repeated attempts using random process conditions, Triclinic identifies the nucleation and growth events and develops a process to control them. That approach improves lot-to-lot consistency and scale-up predictability.
Process variables should be tested because they create the conditions under which nucleation and growth occur. A method that works once at small scale is not robust until the sensitive variables and likely failure modes are understood.
| Control target | Why it matters | Typical Triclinic work |
|---|---|---|
| Desired solid form and polymorphic purity | The process must selectively produce the intended form; the wrong polymorph, hydrate, solvate, or non-crystalline material can change performance or the control strategy. | Evaluate the process-relevant solid-form landscape and the effects of seeding, solvent, temperature, water activity, slurry conditions, and other process variables. |
| Chemical purity | The process must meet target specifications for process impurities and residual solvents. | Systematic crystallization optimization and analytical confirmation. |
| Particle size, morphology, and distribution | Size and habit influence bioavailability, filtration, drying, flow, compressibility, and drug-product quality. | Control nucleation and growth rates, evaluate particle attributes, and adjust process conditions. |
| Chiral resolution | Crystallization can be an economical route to enantiomerically pure material. | Evaluate diastereomeric salt formation, racemate or conglomerate behavior, and crystallographic evidence where chiral resolution is relevant. |
| Scale-up and transfer | Heat- and mass-transfer kinetics and mixing dynamics change with scale and equipment configuration and can alter solid form or particle attributes. | Scale-up risk assessment, manufacturer support, and process-transfer troubleshooting. |
The final crystallization recommendation should identify controllable process parameters, not just successful laboratory conditions. That means documenting which variables affect form, purity, morphology, isolation, drying, and scale-up risk.
Crystallization method development is where form selection becomes a reproducible process. The work should connect solvent, supersaturation, seeding, temperature, water activity, agitation, isolation, drying, and process history to the intended form and material attributes.
Triclinic scopes crystallization studies around the control target: produce the chosen polymorph, avoid hydrate or solvate conversion, improve chemical purity, manage particle habit and size distribution, or provide process evidence for technology transfer.
Use this decision tree to connect form selection, form control, formulation, process development, method development, release testing, stability, and lifecycle risk before the examples and publications section.
A crystallization method is not robust until it controls how the desired form is reached and how unwanted forms are avoided. Kinetic products, metastable intermediates, hydrates, solvates, particle habit, and residual amorphous material can all be created during the process.
Development should connect nucleation pathway, aging, water activity, temperature, solvent history, seeding, mixing, isolation, drying, and post-processing to the selected form and required material attributes.
| Decision signal | What to test | Actionable output |
|---|---|---|
| Kinetic pathway | Fast nucleation, surface evaporation, antisolvent addition, or temperature shocks can create forms not seen under equilibrium conditions. | Screen process-relevant pathways and evaluate whether seeding improves control of the intended form. |
| Thermodynamic endpoint | Slurry aging, competitive slurries, and temperature-dependent solubility reveal which form is most stable at different process stages. | Use stable-form relationships to guide process control. |
| Particle attributes | Habit, size, hydration, and agglomeration affect filtration, drying, flow, and formulation. | Tie particle observations to solid-form and process history. |
Crystallization method development is most effective when connected to the solid-form landscape. It should not be isolated from polymorph, hydrate, solvate, salt, cocrystal, amorphous, or formulation risks.
The same physical attributes that determine API processability - form, morphology, particle size, water content, and stress sensitivity - also affect drug-product manufacturability and stability.
Determine whether an API can exist in multiple crystalline forms and whether form differences change solubility, dissolution, stability, manufacturing, drug-product performance, or IP.
View serviceScreen ionizable APIs for counterions that improve crystallinity, solubility, dissolution, stability, manufacturability, or developability while controlling disproportionation risk.
View serviceUse coformer selection, phase-diagram logic, crystallization methods, and formulation strategy to improve properties and expand solid-form options.
View serviceCharacterize non-crystalline materials, local order, recrystallization risk, spray drying feasibility, polymer selection, drug loading, and solid-dispersion stability.
View serviceResolve form conversion, failed crystallizations, process sensitivity, stability drift, unexplained PK/dissolution changes, and batch-to-batch material differences.
View serviceIt reproducibly produces the intended form with acceptable chemical purity, polymorphic purity, particle attributes, yield, and downstream performance across relevant scale and process variation.
Yes. Crystallization is often an effective industrial purification method and can reduce process impurities or residual solvents when optimized correctly.
Yes. Triclinic can develop background information for form control, support scale-up, evaluate vendor processes, and troubleshoot OOS or transfer issues.
Solvent composition, supersaturation, nucleation history, seeding, temperature profile, antisolvent addition, water activity, agitation, aging, isolation, washing, and drying can all affect solid form, purity, habit, and particle attributes.
Send the material history, current data package, process conditions, development objective, and timeline. Triclinic will route the request to the right solid-form scientist.
